Preview

Rational Pharmacotherapy in Cardiology

Advanced search

LONG-TERM THERAPY WITH ACETYLSALICYLIC ACID. HOW TO AVOID THE POSSIBLE COMPLICATIONS?

https://doi.org/10.20996/1819-6446-2010-6-5-703-708

Full Text:

Abstract

Data about efficacy and safety of long-term therapy with acetylsalicylic acid in patients with cardiovascular diseases are presented. The main practical ways to reduce the possible gastrointestinal complications of the treatment are discussed.

About the Author

I. V. Zhirov
Moscow State University of Medicine and Dentistry
Russian Federation
Delegatskaya ul. 20/1, Moscow, 127473


References

1. Chazov E.I. How to reduce mortality from cardiovascular diseases. Ter Arkh 2008;80(8):11-6. Russian (Чазов Е.И. Пути снижения смертности от сердечно–сосудистых заболеваний. Терапевтический архив 2008; 80(8): 11-16).

2. Tereshchenko S.N., Dzhaiani N.A. Antithrombotic therapy as a basis for prevention of cardiovascular complications. Focus on acetylsalicylic acid. Trudnyy patsient 2008;11: 25-32. Russian (Терещенко С.Н., Джаиани Н.А. Антитромботическая терапия как основа профилактики сердечно-сосудистых осложнений. Фокус на ацетилсалициловую кислоту. Трудный пациент 2008;11: 25-32).

3. Panchenko E.P.,Kropacheva E.S. Guidelines for antithrombotic therapy in patientswith stable manifestations of atherothrombosis. Ateroskleroz 2009; 1(2): 38-54. Russian (Панченко Е.П., Кропачева Е.С. Рекомендации по антитромботической терапии у больных со стабильными проявлениями атеротромбоза. Атеросклероз 2009; 1(2): 38-54).

4. Lupanov V.P. The use of aspirin for secondary prevention of coronary heart disease. Russkiy meditsinskiy zhurnal 2005; 13(15):1053-1056. Russian (Лупанов В.П. Применение ацетилсалициловой кислоты с целью вторичной профилактики коронарной болезни сердца. Русский медицинский журнал 2005; 13(15):1053-1056).

5. Lupanov V.P. The role of aspirin in prevention of atherosclerosis and its complications. Russkiy meditsinskiy zhurnal 2007; 15(16): 1245-1248. Russian (Лупанов В.П. Роль ацетилсалициловой кислотыв профилактике атеросклероза и его осложнений. Русский медицинский журнал 2007; 15(16): 1245- 1248).

6. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373(9678):1849-1860.

7. Patrono C., Baigent C. Antiplatelet therapy: aspirin for asymptomatic atherosclerosis? Nat Rev Cardiol 2010;7(6):306-7.

8. Ogawa H., Nakayama M., Morimoto T. et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008;300(18):2134- 2141.

9. Belch J., MacCuish A., Campbell I. et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840.

10. De Berardis G., Sacco M., Strippoli G.F. et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009; 339: b4531.

11. Haynes R., Bowman L., Armitage J. Aspirin for primary prevention of vascular disease in people with diabetes. BMJ 2009; 339:b4596.

12. National guidelines for diagnosis and treatment of hypertension. The Experts Committee of RMSAH and RSSC. Kardiovaskulyarnaya terapiya i profilaktika 2008; 7(6) prilozhenie 2:1-32. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертонии. Комитет экспертов РМОАГ и ВНОК. Кардиоваскулярная терапия и профилактика 2008; 7(6) приложение 2:1-32).

13. National guidelines for diagnosis and treatment of stable stenocardia. The Experts Committee of RSSC. Kardiovaskulyarnaya terapiya i profilaktika 2008; 7(6) prilozhenie 4:1-32. Russian (Национальные рекомендации по диагностике и лечению стабильной стенокардии. Комитет экспертов ВНОК. Кардиоваскулярная терапия и профилактика 2008;7(6) приложение 4:1-32).

14. Pearson T.A., Blair S.N, Daniels S.R. et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. AmericanHeart Association Science Advisory and Coordinating Committee. Circulation 2002;106(3):388-391.

15. Mancia G., De Backer G., Dominiczak A. et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).J Hypertens 2007;25(6):1105- 87.

16. National guidelines for diagnosis and treatment of patients with myocardial infarction. The Experts Committee of RSSC. Kardiovaskulyarnaya terapiya i profilaktika 2008; 6(8) prilozhenie 1:1-32. Russian (Национальные рекомендации по диагностике и лечению больных острым инфарктом миокарда с подъемом сегмента ST ЭКГ. Комитет экспертов ВНОК. Кардиоваскулярная терапия и профилактика 2008;6(8) приложение 1:1-32).

17. Van de Werf F., Bax J., BetriuA. et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction ofthe European Society of Cardiology. Eur HeartJ. 2008 Dec; 29(23):2909- 45.

18. Okrainec K., Platt R., Pilote L., Eisenberg M.J. Cardiac medical therapy in patients after undergoing coronary artery bypass graft surgery: a review of randomized controlled trials. J Am Coll Cardiol 2005;45(2):177-184.

19. Samko A.N., Bakashvili N.G, Lupanov V.P. et al. Everolimus-coated stent to treat patients with various forms of coronary heart disease. Kardiologicheskiy vestnik 2009: I (XVI) 1: 29-32. Russian (Самко А.Н., Бакашвили Н.Г, Лупанов В.П. и др. Покрытые эверолимусом стенты для лечения больных с различными формами ишемической болезни сердца. Кардиологический вестник 2009: I (XVI) 1: 29-32).

20. Savage M.P., Goldberg S., Bove A.A. et al. Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (MHEART II). Circulation 1995; 92(11): 3194-3200.

21. Lanza F.L. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998;93(11):2037-46.

22. Yusuf S., Zhao F., Mehta S.R. et al. Effect of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST elevation. The CURE trial investigators. N Engl J Med 2001; 345(7): 494-502.

23. Bhatt D.L., Scheiman J., Abraham N.S. et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinalrisks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008;52(18):1502-1517

24. Scheiman J.M. Strategies to reduce the GI risks of antiplatelet therapy. Rev Cardiovasc Med 2005;6 Suppl 4:S23-31.

25. García Rodríguez L.A., Hernández-Díaz S., de Abajo F.J. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol 2001;52(5):563-571.

26. Drug facts and comparisons 2007. Philadelphia: Lippincott Williams & Wilkins; 2006.

27. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehab 2007;14 (Supp 2): E1-E40.


For citation:


Zhirov I.V. LONG-TERM THERAPY WITH ACETYLSALICYLIC ACID. HOW TO AVOID THE POSSIBLE COMPLICATIONS? Rational Pharmacotherapy in Cardiology. 2010;6(5):703-708. (In Russ.) https://doi.org/10.20996/1819-6446-2010-6-5-703-708

Views: 308


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)